# EDGAR Filing Document

**Accession Number:** 0001534133
**File Stem:** 0001193125-25-151240
**Filing Date:** 2025-6
**Character Count:** 9574
**Document Hash:** 318779ba5f25f64772908d548fe55dff
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-151240.hdr.sgml**: 20250627

**ACCESSION NUMBER**: 0001193125-25-151240

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250627

**DATE AS OF CHANGE**: 20250627

**EFFECTIVENESS DATE**: 20250627

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CalciMedica, Inc.
- **CENTRAL INDEX KEY:** 0001534133
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 452120079
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-288287
- **FILM NUMBER:** 251086209

**BUSINESS ADDRESS:**
- **STREET 1:** 505 COAST BOULEVARD SOUTH
- **STREET 2:** SUITE 307
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037
- **BUSINESS PHONE:** 858-952-5500

**MAIL ADDRESS:**
- **STREET 1:** 505 COAST BOULEVARD SOUTH
- **STREET 2:** SUITE 307
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CalciMedica, Inc. /DE/
- **DATE OF NAME CHANGE:** 20230322

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GRAYBUG VISION, INC.
- **DATE OF NAME CHANGE:** 20170717

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GRAYBUG, Inc.
- **DATE OF NAME CHANGE:** 20150303

**As filed with the Securities and Exchange Commission on June 27, 2025** 

**Registration No. 333-288287** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**POST-EFFECTIVE AMENDMENT NO. 1** 

**TO** 

**FORM S-8**

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## CalciMedica, Inc.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **45-2120079** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **505 Coast Boulevard South, Suite 307**<br> **La Jolla, California** | **92037** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**2023 Equity Incentive Plan** 

**2023 Employee Stock Purchase Plan** 

**(Full titles of the plans)** 

**A. Rachel Leheny, Ph.D.** 

**Chief Executive Officer** 

**505 Coast Boulevard South, Suite 307** 

**La Jolla, California 92037** 

**(858) 952-5500**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

---

| | |
|:---|:---|
| **Thomas A. Coll**<br> **Carlos Ramirez**<br> **Cooley LLP**<br> **10265 Science Center Drive**<br> **San Diego, California 92121** | **John M. Dunn**<br> **General Counsel**<br> **505 Coast Boulevard South, Suite 307**<br> **La Jolla, California 92037** |
| **(858) 550-6000** | **(858) 952-5500** |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

This Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 (Registration No. 333-288287) previously filed with the SEC on June 24, 2025 (the "Registration Statement") is being filed solely for the purpose of filing Exhibit 23.3 thereto, which was inadvertently omitted when the Registration Statement was filed. All other portions of the Registration Statement, as previously filed, remain unchanged.

**PART I** 

**ITEM 8. EXHIBITS.** 

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| &nbsp;&nbsp;&nbsp;&nbsp;4.1 | [Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed with the SEC on March 22, 2023).](http://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex31.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.2 | [Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K, filed with the SEC on March 22, 2023).](http://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex32.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.3 | [Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant's Quarterly Report on Form 10-Q, filed with the SEC on November 12, 2020).](http://www.sec.gov/Archives/edgar/data/1534133/000156459020053539/gray-ex32_105.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;5.1\*\* | [Opinion of Cooley LLP.](http://www.sec.gov/Archives/edgar/data/1534133/000119312525145764/d949209dex51.htm) |
| 23.1\*\* | [Consent of Baker Tilly, US, LLP, Independent Registered Public Accounting Firm.](http://www.sec.gov/Archives/edgar/data/1534133/000119312525145764/d949209dex231.htm) |
| 23.2\*\* | [Consent of Cooley LLP. Reference is made to Exhibit 5.1.](http://www.sec.gov/Archives/edgar/data/1534133/000119312525145764/d949209dex51.htm) |
| 23.3\* | [Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.](d917898dex233.htm) |
| 24.1\*\* | [Power of Attorney (included on the signature page of the Registrant's Registration Statement on Form S-8 (Registration No. 333-288287) filed with the SEC on June 24, 2025).](http://www.sec.gov/Archives/edgar/data/1534133/000119312525145764/d949209ds8.htm#sig) |
| 99.1\*\* | [CalciMedica, Inc. 2023 Equity Incentive Plan.](http://www.sec.gov/Archives/edgar/data/1534133/000119312525145764/d949209dex991.htm) |
| 99.2 | [Form of Option Grant Notice and Option Agreement under CalciMedica, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registrant's Current Report on Form 8-K, filed with the SEC on March 22, 2023).](http://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex107.htm) |
| 99.3 | [Forms of Restricted Stock Unit Grant Notice and Unit Award Agreement under CalciMedica, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 to the Registrant's Current Report on Form 8-K, filed with the SEC on March 22, 2023).](http://www.sec.gov/Archives/edgar/data/1534133/000119312523076714/d485425dex108.htm) |
| 99.4 | [CalciMedica, Inc. 2023 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.9 to the Registrant's Quarterly Report on Form 10-Q, filed with the SEC on May 12, 2023).](http://www.sec.gov/Archives/edgar/data/1534133/000095017023021775/calc-ex10_9.htm) |

---

\* Filed herewith.

\*\* Previously filed.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of La Jolla, State of California, on June 27, 2025.

---

| | |
|:---|:---|
| **CALCIMEDICA, INC.** | **CALCIMEDICA, INC.** |
| By: | /s/ A. Rachel Leheny, Ph.D. |
|  | A. Rachel Leheny, Ph.D. |
|  | Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act of 1933, as amended, this Amendment No. 1 to the Registration Statement on Form S-8, has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /S/ A. RACHEL LEHENY, PH.D.<br> A. Rachel Leheny, Ph.D. | Chief Executive Officer and Director<br>*(Principal Executive Officer)* | June 27, 2025 |
| /S/ STEPHEN BARDIN<br> Stephen Bardin | Chief Financial Officer<br> *(Principal Financial and Accounting Officer)* | June 27, 2025 |
| \*<br> Robert N. Wilson | Chairman | June 27, 2025 |
| \*<br> Alan Glicklich | Director | June 27, 2025 |
| \*<br> Frederic Guerard, Pharm.D. | Director | June 27, 2025 |
| \*<br> Fred Middleton | Director | June 27, 2025 |
| \*<br> Eric W. Roberts | Director | June 27, 2025 |
| \*<br> Allan Shaw | Director | June 27, 2025 |

---

---

| | |
|:---|:---|
| \*By: | /s/ A. RACHEL LEHENY, PH.D. |
|  | A. Rachel Leheny, Ph.D. |
|  | Attorney-in-Fact |

---

## Exhibit 23.3

**Exhibit 23.3** 

**Consent of Independent Registered Public Accounting Firm** 

We consent to the incorporation by reference in the Post-Effective Amendment No. 1 to the Registration Statement (Form S-8 No. 333-288287) pertaining to the 2023 Equity Incentive Plan and 2023 Employee Stock Purchase Plan of CalciMedica, Inc. of our report dated March 28, 2024 (except for the Segment Information section of Note 2, as to which the date is March 27, 2025), with respect to the consolidated financial statements of CalciMedica, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

San Diego, California

June 27, 2025